JPWO2022018875A1 - - Google Patents
Info
- Publication number
- JPWO2022018875A1 JPWO2022018875A1 JP2022538564A JP2022538564A JPWO2022018875A1 JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1 JP 2022538564 A JP2022538564 A JP 2022538564A JP 2022538564 A JP2022538564 A JP 2022538564A JP WO2022018875 A1 JPWO2022018875 A1 JP WO2022018875A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Emergency Medicine (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121960A JP7168734B2 (ja) | 2020-07-22 | 2021-07-26 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| JP2022172687A JP2023011759A (ja) | 2020-07-22 | 2022-10-27 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/028575 WO2022018875A1 (ja) | 2020-07-22 | 2020-07-22 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2022018875A1 true JPWO2022018875A1 (enrdf_load_stackoverflow) | 2022-01-27 |
Family
ID=79729374
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538564A Pending JPWO2022018875A1 (enrdf_load_stackoverflow) | 2020-07-22 | 2020-07-22 | |
| JP2021121960A Active JP7168734B2 (ja) | 2020-07-22 | 2021-07-26 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| JP2022172687A Pending JP2023011759A (ja) | 2020-07-22 | 2022-10-27 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121960A Active JP7168734B2 (ja) | 2020-07-22 | 2021-07-26 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| JP2022172687A Pending JP2023011759A (ja) | 2020-07-22 | 2022-10-27 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (3) | JPWO2022018875A1 (enrdf_load_stackoverflow) |
| KR (2) | KR102550455B1 (enrdf_load_stackoverflow) |
| WO (1) | WO2022018875A1 (enrdf_load_stackoverflow) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ789674A (en) | 2020-01-10 | 2025-07-25 | Immuneering Corp | Mek inhibitors and therapeutic uses thereof |
| JP7268255B1 (ja) * | 2021-07-21 | 2023-05-02 | 中外製薬株式会社 | アリールアミド誘導体の製造方法 |
| US20250262194A1 (en) * | 2022-04-20 | 2025-08-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical for treating or preventing cancer |
| EP4551558A2 (en) * | 2022-07-08 | 2025-05-14 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
| WO2025007811A1 (zh) * | 2023-07-06 | 2025-01-09 | 成都华健未来科技有限公司 | 一类芳香酰胺类衍生物及其用途 |
| WO2025063275A1 (ja) * | 2023-09-21 | 2025-03-27 | 中外製薬株式会社 | アリールアミド誘導体の製造方法 |
| WO2025146040A1 (zh) * | 2024-01-01 | 2025-07-10 | 华健未来（成都）科技股份有限公司 | 芳香酰肼类衍生物及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4931419B2 (ja) * | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用 |
| JP4842137B2 (ja) * | 2003-11-19 | 2011-12-21 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋのヘテロ環系阻害剤及びその使用方法 |
| MY144232A (en) * | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| EP2604260B1 (en) * | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
| US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| JP2016034900A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法 |
| CN109988105A (zh) * | 2014-01-27 | 2019-07-09 | 天津滨江药物研发有限公司 | 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法 |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| EP4186506A4 (en) | 2020-07-22 | 2024-08-07 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION CONTAINING AN ARYLAMIDE DERIVATIVE |
-
2020
- 2020-07-22 JP JP2022538564A patent/JPWO2022018875A1/ja active Pending
- 2020-07-22 WO PCT/JP2020/028575 patent/WO2022018875A1/ja active Application Filing
-
2021
- 2021-07-21 KR KR1020210095267A patent/KR102550455B1/ko active Active
- 2021-07-26 JP JP2021121960A patent/JP7168734B2/ja active Active
-
2022
- 2022-10-27 JP JP2022172687A patent/JP2023011759A/ja active Pending
-
2023
- 2023-06-26 KR KR1020230081877A patent/KR20230098762A9/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022145416A (ja) | 2022-10-04 |
| KR20230098762A9 (ko) | 2024-03-25 |
| JP2023011759A (ja) | 2023-01-24 |
| JP7168734B2 (ja) | 2022-11-09 |
| KR20220012195A (ko) | 2022-02-03 |
| WO2022018875A1 (ja) | 2022-01-27 |
| KR20230098762A (ko) | 2023-07-04 |
| KR102550455B1 (ko) | 2023-06-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220630 |